Law360, New York (December 08, 2011, 5:51 PM ET) -- Celgene Corp. and Novartis AG recently hit Teva Pharmaceuticals USA Inc. with a fresh patent infringement suit in New Jersey over Teva’s plan to market a generic version of attention deficit hyperactivity disorder drug Focalin XR, the latest in a long-running battle between the companies.
The plaintiffs claim the suit, filed Dec. 2, was prompted by Teva USA, the American unit of Israel-based Teva Pharmaceutical Industries Ltd., which updated an Abbreviated New Drug Application filed with the U.S. Food and Drug Administration, adding 25-mg and 35-mg...
Novartis, Celgene Hit Teva Again Over ADHD Drug Patents
To view the full article, take a free trial now.
